Neuroplasticity

Neuroplasticity covers every mechanism by which the nervous system alters itself in response to activity. At the fastest scale it is a change in synaptic weight: trafficking of AMPA receptors into or out of the postsynaptic membrane, producing long-term potentiation or depression. Over hours to days it is structural, as dendritic spines form, enlarge and retract. Over weeks it is systems-level, as cortical maps reallocate territory. The organising principle is Hebbian: coincident pre- and postsynaptic activity strengthens a connection, while homeostatic scaling keeps overall firing rates stable.

The experimental foundation is old and solid. Bliss and Lomo described long-term potentiation in rabbit hippocampus in 1973. Hubel and Wiesel's ocular dominance work showed plasticity is gated by developmental critical periods. In humans, constraint-induced movement therapy after stroke forces use of the affected limb, and cortical representation shifts accordingly. More recently, two-photon imaging in rodent frontal cortex has shown rapid dendritic spine formation after single doses of ketamine.

Plasticity is a capacity, not a benefit. The same molecular machinery that supports skill learning also entrenches chronic pain, addiction and post-traumatic associations, so a compound that raises plasticity raises the rate of change without specifying its direction. What determines outcome is what the circuit is doing while it is plastic, which is why plasticity-promoting agents are increasingly paired with training or therapy rather than given alone.

The marketing error is to treat a peripheral biomarker as a plasticity readout. Serum brain-derived neurotrophic factor, the number most often cited, is largely platelet-derived, varies with blood handling, and has no established relationship with synaptic change in the human brain.